425702-91-6

Basic information

• Product Name: 6-BROMO-1,2,4-TRIAZOLO[4,3-A]PYRIDIN-3(2H)-ONE
• Synonyms: 6-BROMO-1,2,4-TRIAZOLO[4,3-A]PYRIDIN-3(2H)-ONE;6-Bromo-[1,2,4]triazolo[4,3-a]pyridin-3(2H)
• CAS NO: 425702-91-6
• Molecular Formula: C6H4BrN3O
• Molecular Weight: 214.03
• Mol File: 425702-91-6.mol
• Article Data: 11

Chemical Properties

• Appearance: /
• Density: 2.09 g/cm³
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 7.17±0.40(Predicted)
• CAS DataBase Reference: 6-BROMO-1,2,4-TRIAZOLO[4,3-A]PYRIDIN-3(2H)-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-BROMO-1,2,4-TRIAZOLO[4,3-A]PYRIDIN-3(2H)-ONE(425702-91-6)
• EPA Substance Registry System: 6-BROMO-1,2,4-TRIAZOLO[4,3-A]PYRIDIN-3(2H)-ONE(425702-91-6)

Safety Data

• Hazardous Substances Data: 425702-91-6(Hazardous Substances Data)

Usage

General Description

6-Bromo-1,2,4-triazolo[4,3-a]pyridin-3(2H)-one is a chemical compound with the molecular formula C5H3BrN4O. It is a heterocyclic compound that contains a pyridine ring fused to a 1,2,4-triazole ring, with a bromine atom attached at the 6-position of the triazole ring. 6-BROMO-1,2,4-TRIAZOLO[4,3-A]PYRIDIN-3(2H)-ONE has potential applications in the field of medicinal chemistry due to its structural features that make it a valuable scaffold for the design and development of new pharmaceutical compounds. Additionally, it may also have applications in the field of agrochemicals or materials science. Further research is needed to explore the potential uses and properties of 6-bromo-1,2,4-triazolo[4,3-a]pyridin-3(2H)-one.

Upstream product

• 77992-44-0 5-bromo-2-hydrazinylpyridine 
• 530-62-1 1,1'-carbonyldiimidazole 
• 77992-44-0 5-bromo-2-hydrazineylidene-1,2-dihydropyridine 
• 766-11-0 5-bromo-2-fluoropyridine 
• 624-28-2 2,5-dibromopyridine 
• 32315-10-9 bis(trichloromethyl) carbonate 

Downstream Products

• 1354198-55-2 2-((3-ethyl-1,2,4-oxadiazol-5-yl)methyl)-6-(4-(trifluoromethoxy)phenyl)-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one 
• 1354200-21-7 2-((3-methylisoxazol-5-yl)methyl)-6-(4-(trifluoromethoxy)phenyl)-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one 
• 1354200-57-9 2-((4-methyloxazol-2-yl)methyl)-6-(4-(trifluoromethoxy)phenyl)-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one 
• 1354198-43-8 2-((5-methyl-1,2,4-oxadiazol-3-yl)methyl)-6-(4-(trifluoromethoxy)phenyl)-[1,2,4]triazolo[4,3-a]pyridin-3 (2H)-one 
• 1354198-93-8 6-(4-(4-chlorophenoxy)phenyl)-2-((3-methyl-1,2,4-oxadiazol-5-yl)methyl)-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one 
• 1354200-39-7 2-((5-cyclopropyl-1,3,4-oxadiazol-2-yl)methyl)-6-(4-(4-fluorophenoxy)phenyl)-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one 
• 1354200-03-5 6-(4-(4-fluorophenoxy)phenyl)-2-((5-(hydroxymethyl)-1,2,4-oxadiazol-3-yl)methyl)-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one 
• 1354199-97-5 6-(4-(4-fluorophenoxy)phenyl)-2-((5-methyl-1,2,4-oxadiazol-3-yl)methyl)-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one 
• 1354199-32-8 6-(4-(4-fluorophenoxy)phenyl)-2-((3-methyl-1,2,4-oxadiazol-5-yl)methyl)-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one 
• 1354200-59-1 2-((4-cyclopropyloxazol-2-yl)methyl)-6-(4-(trifluoromethoxy)phenyl)-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one 
• 1354198-49-4 2-((3-(2,6-dichlorophenyl)-1,2,4-oxadiazol-5-yl) methyl)-6-(4-(trifluoromethoxy)phenyl)-[1,2,4]triazolo [4,3-a]pyridin-3(2H)-one 

Relevant articles and documents

TRIAZOLOPYRIDIN-3-ONES OR THEIR SALTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME

The present technology provides triazolopyridin-3-ones or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. The triazolopyridin-3-ones or their pharmaceutically acceptable salts exhibit inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).

TRIAZOLONES DERIVATIVES FOR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE

The present invention relates to a compound having the general formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, prodrug, tautomer, racemate, codrug, cocrystal, enantiomer, or diastereomer or mixture thereof, which is useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.

Discovery of triazolopyridinone GS-462808, a late sodium current inhibitor (Late INai) of the cardiac Nav1.5 channel with improved efficacy and potency relative to ranolazine

Previously we disclosed the discovery of potent Late INa current inhibitor 2 (GS-458967, IC50 of 333 nM) that has a good separation of late versus peak Nav1.5 current, but did not have a favorable CNS safety window due to high brain penetration (3-fold higher partitioning into brain vs plasma) coupled with potent inhibition of brain sodium channel isoforms (Nav1.1, 1.2, 1.3). We increased the polar surface area from 50 to 84 ?2 by adding a carbonyl to the core and an oxadiazole ring resulting in 3 GS-462808 that had lower brain penetration and serendipitously lower activity at the brain isoforms. Compound 3 has an improved CNS window (>20 rat and dog) relative to 2, and improved anti-ischemic potency relative to ranolazine. The development of 3 was not pursued due to liver lesions in 7 day rat toxicology studies.